Get informed when a big investor buys or sells
+ Follow-99.48%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Cyclopharm Limited (CYC.AX) currently reports a ROE of -99.48%. That is below the sector sector average of 10.27%. Use the charts on this page to explore Cyclopharm Limited's ROE history and peer comparisons.
Cyclopharm Limited's ROE of -99.48% is lower than the its sector sector average of 10.27%. That is roughly 1069.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Cyclopharm Limited's current -99.48% should be judged against industry norms (sector average: 10.27%) and against CYC.AX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -99.48%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 10.27%. From there, open related valuation or income-statement pages for Cyclopharm Limited, and consider following CYC.AX for alerts when major investors trade the stock.